Claret Capital Partners exceeds target with €575M growth debt fund for European innovators

Claret Capital Partners has successfully closed its €575 million fourth European Growth Capital Fund, surpassing its initial €500 million objective. This fund targets technology, life sciences, and impact-focused companies across Europe, with 32% of its capital already deployed to back over 27 companies such as Billie, Cinclus Pharma, PRODA, Inventiva, and Surfe.

The fund offers flexible, lower-dilution financing for companies seeking international expansion, acquisitions, and product development. Institutional investors, including pension funds, insurers, family offices, and public institutions, as well as private wealth investors through an ELTIF structure, contributed to the final close.

Claret Capital Partners' Managing Partner, David Bateman, expressed that the fund's successful close exceeded expectations, reflecting ongoing support from limited partners and co-investors. The firm continues to identify promising high-quality opportunities and actively deploys capital. This development comes after Claret's previous €297 million fund, which closed in 2022 and has since seen exits like Cytora's acquisition by Applied Systems and Tiqets' acquisition by Expedia.

The Managing Partner, Johan Kampe, anticipates increasing demand for flexible, non-dilutive capital as equity markets remain selective, and founders seek ways to scale without unnecessary dilution. Claret Capital Partners aims to expand its pan-European presence following the fund's successful closure, with team members now based in Paris and a planned presence in Berlin.